Arcutis Biotherapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ARQT Nasdaq 2836 www.arcutis.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jun 5th, 2026 2:00 pm
New Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital Psoriasis Published in the American Journal of Clinical Dermatology - Jun 3rd, 2026 6:00 am
Arcutis Management to Present at Goldman Sachs 47th Annual Global Healthcare Conference - May 26th, 2026 2:00 pm
Arcutis Biotherapeutics (ARQT) Is Down 11.0% After Strong Q1 And sNDA For ZORYVE Expansion - May 8th, 2026 11:19 pm
Arcutis Biotherapeutics, Inc. Q1 2026 Earnings Call Summary - May 7th, 2026 6:30 am
Arcutis Biotherapeutics Q1 Earnings Call Highlights - May 6th, 2026 4:59 pm
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Beats Revenue Estimates - May 6th, 2026 3:25 pm
Arcutis Announces First Quarter 2026 Financial Results and Provides Business Update - May 6th, 2026 2:00 pm
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release - Apr 30th, 2026 8:00 am
Will Arcutis Biotherapeutics, Inc. (ARQT) Report Negative Earnings Next Week? What You Should Know - Apr 29th, 2026 8:00 am
Arcutis Submits Supplemental New Drug Application to the FDA for ZORYVE® (roflumilast) Cream 0.05% to Expand Indication for Treatment of Atopic Dermatitis to Infants Down to 3 Months - Apr 27th, 2026 6:00 am
A Look At Arcutis Biotherapeutics (ARQT) Valuation After Recent Share Price Moves - Apr 23rd, 2026 6:16 pm
How The Arcutis Biotherapeutics (ARQT) Narrative Is Shifting Around Zoryve And The $35 Target - Apr 23rd, 2026 12:05 pm
Arcutis’ ZORYVE® (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines - Apr 22nd, 2026 6:00 am
Arcutis Biotherapeutics (ARQT) Presents Positive Phase 2 Data for ZORYVE Cream in Infants - Apr 19th, 2026 9:44 am
Arcutis to Report First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026 - Apr 15th, 2026 2:00 pm
Arcutis Biotherapeutics Targets ZORYVE Expansion, Raises 2026 Outlook and Turns Cash-Flow Positive - Apr 14th, 2026 9:04 pm
Is It Too Late To Revisit Arcutis Biotherapeutics (ARQT) After A 75% One-Year Surge? - Apr 8th, 2026 2:04 pm
Arcutis Stock Up 65% as Director Sells 10,000 Shares Under 10b5-1 Plan. Here's What Investors Should Know - Apr 8th, 2026 5:50 am
How The Arcutis Biotherapeutics (ARQT) Story Is Evolving As Analysts Cluster Around US$35 Targets - Apr 8th, 2026 1:13 am